SUCAMPO PHARMACEUTICALS, INC.
SUCAMPO PHARMACEUTICALS, INC. (SCMP): 3 pipeline candidates · ~63 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
62.6 months
D/E 8.79
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for SUCAMPO PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$75.0M
Quarterly Burn
$5.3M
Runway
62.6 mo
Revenue
$61.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| amitiza | Approved |
| cpp-1x/sulindac | Phase 3 |
| rescula | Approved |
Frequently asked questions
How many drug candidates are in SUCAMPO PHARMACEUTICALS, INC.'s pipeline?
SUCAMPO PHARMACEUTICALS, INC. (SCMP) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SUCAMPO PHARMACEUTICALS, INC.'s lead drug candidate?
SUCAMPO PHARMACEUTICALS, INC.'s most advanced tracked candidate is amitiza (Approved) for Opioid-induced constipation (OIC) in patients with chronic non-cancer pain.
What is SUCAMPO PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SUCAMPO PHARMACEUTICALS, INC. has approximately 62.6 months of cash runway.
Who is the CEO of SUCAMPO PHARMACEUTICALS, INC.?
Peter Greenleaf is the chief executive officer of SUCAMPO PHARMACEUTICALS, INC. (SCMP).
Get the full picture on SUCAMPO PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.